Иммуноморфологическая специфичность HER2-low рака молочной железы

Иммуноморфологическая специфичность HER2-low рака молочной железы

Автор: Михайлов И.В., Еремеева Е.Р., Глазков А.А., Тележникова И.М., Сетдикова Г.Р., Балканов А.С.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Лабораторные и экспериментальные исследования

Статья в выпуске: 5 т.23, 2024 года.

Бесплатный доступ

Оценка уровня инфильтрации опухоль-ассоциированными лимфоцитами (TiLs) уже хорошо зарекомендовала себя как дополнительный инструмент прогнозирования выживаемости при триплнегативном (ТПн) и HER2/neu позитивном (HER2+) подтипах рака молочной железы (РМЖ). Последнее время РМЖ, в том числе вышеобозначенных подтипов, характеризующийся низкой/неопределенной экспрессией HER2/neu, выделяют в отдельную группу, получившую обозначение HER2-low РМЖ. Взаимозависимость между клинико-морфологическими параметрами и инфильтрацией иммунокомпетентными клетками, включающими опухоль-ассоциированные макрофаги (ОАМ), и HER2-low РМЖ, на данный момент не изучена. Цель исследования - выявление значимых взаимосвязей между уровнем субпопуляций иммунокомпетентных клеток (TiLs + ОАМ) и клинико-морфологическими параметрами HER2-low (экспрессия HER2/neu +1 или +2) РМЖ. Материал и методы. В рамках исследования изучен операционный материал (мастэктомия/резекция) 33 пациенток с HER2-low РМЖ. Подсчет TiLs и оценку уровня субпопуляций иммунокомпетентных клеток (ИКК: Т-хелперов, Т-киллеров, М1 и М2 макрофагов) методом ИГХ осуществляли во внутриопухолевых участках и в инвазивном крае первичной опухоли.

Еще

Рак молочной железы, негативный her2-neu статус, her2-low статус, опухоль-ассоциированные макрофаги, периневральная инвазия

Короткий адрес: https://sciup.org/140307921

IDR: 140307921   |   DOI: 10.21294/1814-4861-2024-23-5-47-58

Список литературы Иммуноморфологическая специфичность HER2-low рака молочной железы

  • Pernas S., Tolaney S.M. Clinical trial data and emerging strategies: HER2-positive breast cancer. Breast Cancer Res Treat. 2022; 193(2): 281-91. https://doi.org/10.1007/s10549-022-06575-7.
  • Denkert C., Seither F., Schneeweiss A., Link T., Blohmer J.U., Just M., Wimberger P., Forberger A., Tesch H., Jackisch C., Schmatloch S., Reinisch M., Solomayer E.F., Schmitt W.D., Hanusch C., Fasching P.A., Lübbe K., Solbach C., Huober J., Rhiem K., Marmé F., Reimer T., Schmidt M., Sinn B.V., Janni W., Stickeler E., Michel L., Stötzer O., Hahnen E., Furlanetto J., Seiler S., Nekljudova V., Untch M., Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021; 22(8): 1151-61. https://doi.org/10.1016/S1470-2045(21)00301-6.
  • Jin J., Li B., Cao J., Li T., Zhang J., Cao J., Zhao M., Wang L., Wang B., Tao Z., Hu X. Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer. J Transl Med. 2023; 21(1): 360. https://doi.org/10.1186/s12967-023-04076-9.
  • Vtorushin S.V., Krakhmal' N.V., Zavalishina L.E., Kuznetsova O.A., Moskvina L.V., Frank G.A. Opredelenie HER2-statusa kartsinom razlichnykh lokalizatsii. Arkhiv patologii. 2023; 85(6): 31-46. https://doi.org/10.17116/patol20238506131.
  • Schlam I., Tolaney S.M., Tarantino P. How I treat HER2-low advanced breast cancer. Breast. 2023; 67: 116-23. https://doi.org/10.1016/j.breast.2023.01.005.
  • Moy B., Wolff A.C., Rumble R.B., Allison K.H., Carey L.A. Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncol Pract. 2023; 19(8): 547-50. https://doi.org/10.1200/OP.23.00047.
  • Vaziri Fard E., Ali Y., Wang X.I., Saluja K., H Covinsky M., Wang L., Zhang S. Tumor-Infltrating Lymphocyte Volume Is a Better Predictor of Disease-Free Survival Than Stromal Tumor-Infltrating Lymphocytes in Invasive Breast Carcinoma. Am J Clin Pathol. 2019; 152(5): 656-65. https://doi.org/10.1093/ajcp/aqz088.
  • García-Martínez E., Gil G.L., Benito A.C., González-Billalabeitia E., Conesa M.A., García García T., García-Garre E., Vicente V., Ayala de la Peña F. Tumor-infltrating immune cell profles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014; 16(6): 488. https://doi.org/10.1186/s13058-014-0488-5.
  • Skriver S.K., Jensen M.B., Knoop A.S., Ejlertsen B., Laenkholm A.V. Tumour-infltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. Breast Cancer Res. 2020; 22(1): 46. https://doi.org/10.1186/s13058-020-01285-8.
  • Salgado R., Denkert C., Campbell C., Savas P., Nuciforo P., Aura C., de Azambuja E., Eidtmann H., Ellis C.E., Baselga J., PiccartGebhart M.J., Michiels S., Bradbury I., Sotiriou C., Loi S. TumorInfltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol. 2015; 1(4): 448-54. https://doi.org/10.1001/jamaoncol.2015.0830. Erratum in: JAMA Oncol. 2015; 1(4): 544. https://doi.org/10.1001/jamaoncol.2015.1805. Erratum in: JAMA Oncol. 2015; 1(8): 1172. https://doi.org/10.1001/jamaoncol.2015.4229. Nucifero, Paolo [corrected to Nuciforo, Paolo]. Erratum in: JAMA Oncol. 2019; 5(1): 122. https://doi.org/10.1001/jamaoncol.2018.5678.
  • Perez E.A., Ballman K.V., Tenner K.S., Thompson E.A., Badve S.S., Bailey H., Baehner F.L. Association of Stromal Tumor-Infltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. JAMA Oncol. 2016; 2(1): 56-64. https://doi.org/10.1001/jamaoncol.2015.3239.
  • Fernandez-Martinez A., Pascual T., Singh B., Nuciforo P., Rashid N.U., Ballman K.V., Campbell J.D., Hoadley K.A., Spears P.A., Pare L., Brasó-Maristany F., Chic N., Krop I., Partridge A., Cortés J., Llombart-Cussac A., Prat A., Perou C.M., Carey L.A. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs TumorInfltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. JAMA Oncol. 2023; 9(4): 490-9. https://doi.org/10.1001/jamaoncol.2022.6288.
  • Pruneri G., Gray K.P., Vingiani A., Viale G., Curigliano G., Criscitiello C., Láng I., Ruhstaller T., Gianni L., Goldhirsch A., Kammler R., Price K.N., Cancello G., Munzone E., Gelber R.D., Regan M.M., Colleoni M. Tumor-infltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Res Treat. 2016; 158(2): 323-31. https://doi.org/10.1007/s10549-016-3863-3.
  • Kiselevskii M.V., Vlasenko R.Ya., Zabotina T.N., Kadagidze Z.G. Prognosticheskaya znachimost' opukhol'-infil'triruyushchikh limfotsitov. Immunologiya. 2019; 40(1): 73-82. https://doi.org/10.24411/0206-4952-2019-11009.
  • Lundgren C., Bendahl P.O., Ekholm M., Fernö M., Forsare C., Krüger U., Nordenskjöld B., Stål O., Rydén L. Tumour-infltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up. Breast Cancer Res. 2020; 22(1): 140. https://doi.org/10.1186/s13058-020-01364-w.
  • Gwak J.M., Jang M.H., Kim D.I., Seo A.N., Park S.Y. Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer. PLoS One. 2015; 10(4). https://doi.org/10.1371/journal.pone.0125728.
  • Mehraj U., Qayoom H., Mir M.A. Prognostic signifcance and targeting tumor-associated macrophages in cancer: new insights and future perspectives. Breast Cancer. 2021; 28(3): 539-55. https://doi.org/10.1007/s12282-021-01231-2.
  • Hendry S., Salgado R., Gevaert T. et al. Assessing Tumor-infltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 2017; 24(5): 235-51. https://doi.org/10.1097/PAP.0000000000000162.
  • Wei C., Yang C., Wang S., Shi D., Zhang C., Lin X., Liu Q., Dou R., Xiong B. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019; 18(1): 64. https://doi.org/10.1186/s12943-019-0976-4.
  • Anderson S., Bartow B.B., Siegal G.P., Huang X., Wei S. The dynamics of HER2-low expression during breast cancer progression. Breast Cancer Res Treat. 2023; 201(3): 437-46. https://doi.org/10.1007/s10549-023-07020-z.
  • van den Ende N.S., Nguyen A.H., Jager A., Kok M., Debets R., van Deurzen C.H.M. Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. Int J Mol Sci. 2023; 24(3): 2969. https://doi.org/10.3390/ijms24032969.
  • Takada K., Kashiwagi S., Asano Y., Goto W., Kouhashi R., Yabumoto A., Morisaki T., Shibutani M., Takashima T., Fujita H., Hirakawa K., Ohira M. Prediction of lymph node metastasis by tumor-infltrating lymphocytes in T1 breast cancer. BMC Cancer. 2020; 20(1): 598. https://doi.org/10.1186/s12885-020-07101-y.
  • Jeong H., Hwang I., Kang S.H., Shin H.C., Kwon S.Y. TumorAssociated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer. J Breast Cancer. 2019; 22(1): 38-51. https://doi.org/10.4048/ jbc.2019.22.e5.
  • Kashyap D., Bal A., Irinike S., Khare S., Bhattacharya S., Das A., Singh G. Heterogeneity of the Tumor Microenvironment Across Molecular Subtypes of Breast Cancer. Appl Immunohistochem Mol Morphol. 2023; 31(8): 533-43. https://doi.org/10.1097/PAI.0000000000001139.
  • Allison E., Edirimanne S., Matthews J., Fuller S.J. Breast Cancer Survival Outcomes and Tumor-Associated Macrophage Markers: A Systematic Review and Meta-Analysis. Oncol Ther. 2023; 11(1): 27-48. https://doi.org/10.1007/s40487-022-00214-3.
  • Zhao X., Qu J., Sun Y., Wang J., Liu X., Wang F., Zhang H., Wang W., Ma X., Gao X., Zhang S. Prognostic signifcance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Oncotarget. 2017; 8(18): 30576-86. https://doi.org/10.18632/oncotarget.15736.
  • Muraro E., Martorelli D., Turchet E., Miolo G., Scalone S., Comaro E., Talamini R., Mastorci K., Lombardi D., Perin T., Carbone A., Veronesi A., Crivellari D., Dolcetti R. A diferent immunologic profle characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Res. 2011; 13(6). https://doi.org/10.1186/bcr3060.
  • Mohamed R.F., Abdelhameed D.H., Mohamed M.A. Combination of Anatomical and Biological Factors to Predict Disease-Free Survival in Breast Cancer. JCO Glob Oncol. 2023; 9. https://doi.org/10.1200/GO.22.00269.
  • Wang X., Zhang L., Zhang X., Luo J., Wang X., Chen X., Yang Z., Mei X., Yu X., Zhang Z., Guo X., Shao Z., Ma J. Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy? Breast Cancer Res Treat. 2021; 190(2): 277-86. https://doi.org/10.1007/s10549-021-06378-2.
  • Mittendorf E.A., Ballman K.V., McCall L.M., Yi M., Sahin A.A., Bedrosian I., Hansen N., Gabram S., Hurd T., Giuliano A.E., Hunt K.K. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J Clin Oncol. 2015; 33(10): 1119-27. https://doi.org/10.1200/JCO.2014.57.2958.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp